Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: StocksDATsoar who wrote (25409)	2/2/2000 11:12:00 PM
From: Snowman	Respond to of 52051

Definitely lots of room on the upside..eom

To: StocksDATsoar who wrote (25409)	2/3/2000 8:42:00 AM
From: Snowman	Read Replies (1) \| Respond to of 52051

PPRT had some nice after hours trading and write up at the street.com" During the day session, Pharmaprint rose 15/32 to 1 7/16, which in the land of microcaps is a gain of 48.4%. Oh, yeah. And that move came on volume of 4.4 million shares. Usually, volume for the herbalist is low six-figures. Tonight, that volume has spilled over into the night session, along with some momentum. It was last up 3/16 to 1 21/32 on 1.4 million shares on Island. The deal, which hasn't been formally signed yet, creates a joint venture to promote Pharmaprint's products across the Pacific. China New Industries will put $6 million in cash into the new venture over the next two years, with an initial stake of $1.5 million. In exchange, it gets a 49% stake. Pharmaprint will own the other 51% in exchange for providing exclusive rights to its products. Company CEO Richard Piazza said that China New Industries approached Pharmaprint with the funding. "Let me explain the transaction," he said. "We were approached by China New Industries. It's a venture fund, depending on the money conversion, in the range of $150 million, which is run by the Chinese government. A lot of the money in the fund goes to support capitalist ventures. Their goal is to create business in China that will create a business investment." Piazza said that Chinese culture is more open to the concept of herbal medicine, with a predilection towards self-directed healthcare. He said that Chinese herbal market is $20 billion strong, opposed to in America, where the herbal market is only $5 billion. "Chinese people have a great interest in self-directed healthcare," Piazza said. He then refuted the stereotype that Chinese dabble in strange forms of herbal medicine, using ingredients that are strange to Western thought. "The more-focused people are spending their money on packaged herbals. It's (China New Industries') belief that we can capitalize on this and build a nice business in China." Per the terms of the deal, Piazza will remain CEO of the joint venture, but management will be local. The first part of the deal focuses on marketing and promoting Pharmaprint as a brand name and quality seal. He said the new venture in the Far East wouldn't distract the company from its efforts domestically. "I would not suggest the future of Pharmaprint is China, it is a component of it," he said. "We look for modest gains in the next two to three years." "I'm focused on building this company," he said. "And I think the stock price will follow the performance of the company. Honestly, I don't follow the stock price."